Danirixin is primarily investigated for its potential therapeutic applications in inflammatory diseases. It functions as a selective CXCR2 antagonist, which makes it effective in targeting and reducing neutrophil-mediated inflammation. This mechanism is particularly relevant in conditions such as chronic obstructive pulmonary disease (COPD), where excessive neutrophil activity contributes to tissue damage and disease progression. By inhibiting CXCR2, it helps in controlling the migration and activation of neutrophils, thereby alleviating inflammation and improving respiratory function. Additionally, its anti-inflammatory properties are being explored in other inflammatory disorders, offering a promising approach to manage diseases driven by similar inflammatory pathways.